Endobiomedika - Company finances
|
EUR
|
2023
From: 2023-01-02
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 15,393 | 14,356 | 13,245 |
| Profit before tax | - | 5,690 | 5,750 |
| Net profit | 9,281 | 5,405 | 5,750 |
| Equity | 9,281 | 14,686 | 20,436 |
| Liabilities | 673 | 3,315 | 424 |
| Non-current assets | 0 | 0 | 0 |
| Current assets | 9,954 | 18,001 | 20,860 |
| Total assets | 9,954 | 18,001 | 20,860 |
|
Taxes paid
|
|||
| STI taxes | 64 | - | 285 |
|
Financial indicators
|
|||
| Revenue change y/y | - | -6.7% | -7.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 93.2% | 30.0% | 27.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 36.8% | 28.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 60.3% | 37.6% | 43.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 39.6% | 43.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.2 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Endobiomedika - Social security debts
The company had no debts to Sodra
Endobiomedika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Endobiomedika, MB, company code 306208897, is a Small partnership active in traditional, complementary and alternative medicine activities. In 2025, the latest financial year, revenue amounted to €13.2K, down 7.7% year on year and 13.9% below the 2023 level of €15.4K. Despite the lower turnover, the company remained profitable, posting net profit of €5.8K in 2025, slightly above €5.4K in 2024 but below €9.3K in 2023. The profit margin improved to 43.4% in 2025 from 37.6% in 2024, after 60.3% in 2023. The balance sheet strengthened over the period: total assets rose to €20.9K in 2025 from €18.0K in 2024 and €10.0K in 2023, while equity increased to €20.4K. Liabilities were only €424 in 2025, reflecting a very low debt position. Key ratios for 2025 indicate solid profitability and efficiency, with ROE at 28.1%, ROA at 27.6%, debt-to-equity at 0.02, and asset turnover at 0.63x.